China Resources Pharmaceutical Group Ltd
HKEX:3320
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.51
6.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Income to Minority Interest
China Resources Pharmaceutical Group Ltd
Income to Minority Interest Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income to Minority Interest | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Income to Minority Interest
-HK$6.9B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Income to Minority Interest
-HK$17.8m
|
CAGR 3-Years
-82%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-18%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Income to Minority Interest
-HK$11.8m
|
CAGR 3-Years
-178%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Income to Minority Interest
¥658k
|
CAGR 3-Years
8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Income to Minority Interest
-¥2.9B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-16%
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Income to Minority Interest
$239k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
China Resources Pharmaceutical Group Ltd
Glance View
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
See Also
What is China Resources Pharmaceutical Group Ltd's Income to Minority Interest?
Income to Minority Interest
-6.9B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Income to Minority Interest amounts to -6.9B HKD.
What is China Resources Pharmaceutical Group Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 5Y
-15%
Over the last year, the Income to Minority Interest growth was -25%. The average annual Income to Minority Interest growth rates for China Resources Pharmaceutical Group Ltd have been -38% over the past three years , -15% over the past five years .
You don't have any saved screeners yet
